Stories

Browse major news stories and see what officials have said.

Tag: executive-action ✕

The Endangered Species Act's Definition of "Harm" Dies the Same Day an Internal Memo Narrows the Law to Intentional Killing Only — 21 Attorneys General Sue, With Connecticut's William Tong Saying Trump Is "Sacrificing Entire Species for Short-Term Corporate and Political Gain"

Two things happened to the Endangered Species Act on September 14, 2026. A final rule rescinding the federal government's longstanding regulatory definition of "harm" — the definition that counted habitat destruction as harm to a protected species — took effect. And, according to an internal memo obtained by The New York Times and reported on September 17, Fish and Wildlife Service Director Brian Nesvik signed guidance reinterpreting the 1973 law so that only *intentional* harm to an individual animal or plant violates it. Accidental killings and injuries arising from economic activity would not. Together the two changes strip the Act of the mechanism environmental lawyers have relied on since the Supreme Court upheld the habitat reading in *Babbitt v. Sweet Home* (1995): the ability to treat destroying a species' home as harming the species. Five days before the rule took effect, on September 9, a coalition of 21 state attorneys general — co-led by Massachusetts AG Andrea Campbell and Washington AG Nick Brown — filed two lawsuits in the Northern District of California against the Fish and Wildlife Service and the National Marine Fisheries Service, seeking to block both the rescission of the "harm" definition and a companion rule stripping automatic protection from newly listed threatened species. Species named in the complaints include the piping plover, the shortnose sturgeon, the leatherback sea turtle and the Southern Resident killer whale, whose population has fallen from 98 whales in 1995 to 74 today. Separately, Sens. Adam Schiff (D-CA) and Sheldon Whitehouse (D-RI) have introduced a Congressional Review Act resolution that would repeal the rule, though it has no path to the floor before the midterms.

“Donald Trump is sacrificing entire species for short-term corporate and political gain. The consequences of these reckless and callous rollbacks cannot be fixed in the next election cycle.”

William Tong (D-CT) · Sep 9, 2026
environment
endangered-species-act
wildlife
5 statements

Trump Adds Nine More Drugmakers to His Most-Favored-Nation Pricing Deals and Asks Congress to Write Them Into Law — and His Health Secretary Says the President Called Him and Dr. Oz "Every Hour of the Day" and Made Clear Their Jobs Depended on It

On Monday, August 31, 2026, President Trump announced from the White House that nine more pharmaceutical manufacturers — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB — had agreed to "most-favored-nation" pricing, under which state Medicaid programs pay the lowest price the manufacturer charges in a comparable wealthy country. That brings the running total to 26 companies, which the White House says covers roughly 89 to 90 percent of the branded drug market, and which the administration projects will save Americans more than $600 billion over a decade. The announcement was staged nine weeks before the midterms, into an affordability argument Democrats have been running against Republicans all year. Trump used it to press Congress: he said the company-by-company deals should be codified in statute so a future president cannot simply let them lapse. The most revealing moment came from inside his own cabinet. Health and Human Services Secretary Robert F. Kennedy Jr., standing beside him, described how the deals got done — Trump calling him and CMS Administrator Mehmet Oz "every hour of the day" and making clear their jobs depended on delivering. Trump's answer, from the same event, was that he had not wanted to follow through: "I didn't want to fire a Kennedy. I wasn't going to do that." Commerce Secretary Howard Lutnick tied the agreements to onshoring pharmaceutical production. The persistent criticism of the program is that the terms are not public. Democrats on the Finance, Ways and Means and Energy and Commerce committees have spent 2026 demanding the texts of the deals — Sen. Ron Wyden and 18 Senate Democrats introduced a Drug Deal Disclosure Act in April — and a Public Citizen analysis found that all 16 companies from the program's earlier rounds raised list prices on 272 products in the first months of 2026. No congressional reaction specific to the August 31 announcement had been recorded as of September 1; the Senate stood adjourned until September 14.

“These agreements are projected to save Americans more than $600 billion over a very short period of time.”

Donald Trump (R-FL) · Aug 31, 2026
health-care
drug-pricing
most-favored-nation
6 statements